DermTech (DermTech) Total Stockholders Equity : $57.18 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is DermTech Total Stockholders Equity?

DermTech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $57.18 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. DermTech's Book Value per Share for the quarter that ended in Dec. 2023 was $1.66. The ratio of a company's debt over equity can be used to measure how leveraged this company is. DermTech's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.95.

DermTech Total Stockholders Equity Historical Data

The historical data trend for DermTech's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DermTech Total Stockholders Equity Chart

DermTech Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

5.85

61.84

229.70

132.35

57.18

DermTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															132.35	107.24	88.08	73.06	57.18

DermTech (NAS:DMTK) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

DermTech's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(57.175	-	0)	/	34.5247
	=	1.66

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

DermTech's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.086	+	51.308)	/	57.175
	=	0.95

DermTech Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of DermTech's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

DermTech (DermTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » DermTech Inc (NAS:DMTK) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

11099 N. Torrey Pines Road, Suite 100, La Jolla, CA, USA, 92037

Website

https://www.dermtech.com

DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.

Executives

Kevin M Sun	officer: Chief Financial Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Claudia Ibarra	officer: Chief Operating Officer	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Ramin Akhavan	officer: General Counsel	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Mark Bryan Aguillard	officer: Chief Commercial Officer	19800 CORDILL LANE, SPICEWOOD TX 78669
Todd Michael Wood	officer: Chief Commercial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Bret Christensen	director, officer: Chief Executive Officer	600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
John Dobak	director, officer: Chief Executive Officer	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Kirk Malloy	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Mark Christopher Capone	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Herm Rosenman	director	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Nathalie Gerschtein Keraudy	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Monica Tellado	director	C/O DERMTECH, INC., 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Enrico Picozza	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037